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Abstract
Background and Objectives: High mortality in pancreas ductal adenocarcinoma (PDAC) is related to delayed diagnosis and lack of cost-effective early
detection strategies. Retrospective studies have demonstrated an association between PDAC and acute pancreatitis (AP). Herein, we explore the incidence of
PDAC in patients with non-biliary and non-alcoholic AP.
Methods: A population-based, retrospective cohort study was conducted utilizing TriNetX (Cambridge, MA). Patients ≥40 years with AP (ICD-10-CM code:
K85) and without biliary AP (K85.1), alcohol-induced AP (K85.2) or chronic pancreatitis (K86.0, K86.1), were identified. The primary outcome was incidence of
PDAC (C25) in patients at defined intervals following AP. We compared the rate
of early-stage diagnosis (stage 1–2) and surgical resection among patients with
and without preceding AP.
Results: The incidence of PDAC ranged from 2.16% (1 year) to 3.43% (5 years).
Patients with PDAC and AP in preceding year were more likely to undergo surgical resection relative to those without AP (10.1% vs. 6.3%, risk ratio 1.62: 95% confidence interval, CI 1.47–1.79). Early-stage diagnosis of PDAC was more frequent
in patients with preceding AP; however, difference was insignificant (p = 0.48;
95% CI 0.64–2.58).
Conclusion: AP is infrequently associated with PDAC and can precede a diagnosis of PDAC in a minority of patients without another known etiology of pancreatitis. Patients with a recent AP are more likely to undergo surgical resection of
PDAC and a trend toward diagnosis at an earlier stage compared to patients with
PDAC and without AP. The impact of AP-related PDAC on survival is unknown.
KEYWORDS

acute pancreatitis, database, pancreas ductal adenocarcinoma, pancreatic neoplasm

This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided
the original work is properly cited.
© 2022 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.
Cancer Medicine. 2022;00:1–9.		

wileyonlinelibrary.com/journal/cam4

|

1

2

1

|

SINGH et al.

  

|

I N T RO DU CT ION

Patients with pancreatic adenocarcinoma (PDAC) have
the lowest 5-year survival rate among all cancers and
this rate has improved modestly from approximately 4%
to 10% over the last 30 years.1 A longitudinal population-
based multinational study of seven common cancer sites
comprising over 3.5 million patients identified PDAC to
have the worst 5-year survival rate of less than 10% in
most countries.2 This lethality is in large part attributed to
late clinical presentation, delay in diagnosis and frequent
discovery of PDAC at unresectable and metastatic stages.
Furthermore, it has been demonstrated that early diagnosis of PDAC is associated with higher probability of surgical resection and improved survival.3,4
Several risk factors have been associated with PDAC,
including chronic pancreatitis, tobacco smoking, selected
inherited genetic variants, family history of PDAC, hereditary pancreatitis and possibly long-standing diabetes mellitus.5–8 Acute pancreatitis has been studied as a risk factor
for PDAC as well as an associated clinical manifestation
concurrent with the diagnosis of PDAC.9–12 However, this
has not been quantified adequately.13,14
Acute pancreatitis can be an early sign of underlying
PDAC. There are a few published retrospective, mostly
population-based studies evaluating the presence and predictive factors of underlying PDAC in patients presenting with
acute pancreatitis.11,15–18 While there is some evidence to
suggest that PDAC is diagnosed at an earlier stage in patients
who present with PDAC during an episode of acute pancreatitis, there is limited prospective data regarding the clinical
stage at diagnosis or survival outcomes.11,16 Moreover, the
frequency of PDAC detection is even higher among patients
over 40 or 50 years of age who present with acute pancreatitis compared to those without pancreatitis.18,19 The risk of
identifying PDAC in these patients is higher in non-biliary,
non-alcoholic etiologies of pancreatitis.17 Diagnosis at an
early stage of PDAC (stages I–II) and subsequent surgical resection is associated with longer survival compared to individuals diagnosed with later stage disease.3,4 Thus, exploring
the hypothesis that diagnosing PDAC at an earlier stage in
patients presenting with acute pancreatitis is a critical one,
and herein we perform a retrospective cohort study utilizing
a health research network based on electronic health records
and insurance claims data.
We aim to determine the incidence of PDAC in patients with non-biliary, non-alcoholic acute pancreatitis at
3 months, and one through 5 years following a diagnosis of
acute pancreatitis. Other objectives include determination
of the rate of surgical resection and diagnosis of PDAC at
an early stage in patients with and without a recent history
of acute pancreatitis. We also aim to describe the anatomical location of PDAC (head, body/tail) in patients with

acute pancreatitis, and evaluate the role of tumor markers (CA-19-9 and CEA) in predicting underlying PDAC in
acute pancreatitis.
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METHODS

This study is a population-based, multi-center, retrospective
cohort study utilizing TriNetX (Cambridge, MA), “a global
federated health research network that provides deidentified data from electronic medical records.” (https://www.
trinetx.com/page/4/#home-slider-3-copy) We searched the
TriNetX platform to obtain aggregated health records from
approximately 70 million patients in 55 health-care organizations (HCO) from May 1, 2011, to April 30, 2021.

2.1
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Study population

Adult patients 40 years and older with a diagnosis of acute
pancreatitis were identified using relevant ICD-
10-
CM
codes (K85). Among these patients, those with biliary-
related acute pancreatitis (K85.1), alcohol-induced acute
pancreatitis (K85.2) and who had a diagnosis of chronic
pancreatitis (ICD-10-CM codes: K86.0, K86.1), were excluded (Figure 1). This subgroup of patients with PDAC
and acute pancreatitis was named acute pancreatitis of
undetermined etiology (APUE). Patients with a diagnosis
of exocrine PDAC were identified using appropriate ICD-
10-CM codes (C25.0, C25.1, C25.2, C25.3, C25.7, C25.8,
C25.9), and those with pancreatic endocrine neoplasms
(ICD-10-CM code: C25.4), were excluded.
To determine the incidence of PDAC in APUE, we identified patients who had at least one visit (inpatient or ambulatory) during each consecutive year for 5 years following
the diagnosis of acute pancreatitis. Patient cohorts were
defined by time of acute pancreatitis diagnosis; acute pancreatitis diagnosed during May 2011–April 2013, May 2013–
April 2015, May 2015–April 2017 and May 2017–April 2019.
In a separate analysis, a subset of patients who had a
diagnosis of acute pancreatitis in the year preceding their
diagnosis of PDAC were also examined for location of cancer within the pancreas (head, body, or tail), cancer stage
and whether they underwent surgical resection. Patients
presenting with acute pancreatitis a day or more following
the diagnosis of PDAC were excluded.
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Comparison group and matching

During the same period 2011–2021, patients with a diagnosis of PDAC and without a prior diagnosis of acute pancreatitis listed in the TriNetx dataset in the past were identified
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F I G U R E 1 Consort flow diagram of
database search and results.
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Research Network
49 Healthcare Organizations (HCO)
69,299,000 Patients

291,014 Adult ( 18 years) Patients with Acute Pancreatitis from 51 HCO

Inclusion Criteria:
• Period: May 1, 2011 to April 30, 2021.
• Age 40 years.
• Acute pancreatitis (ICD-10 code: K85).

198,130 Patients with Acute Pancreatitis 40 years During the Study Period
Exclusion Criteria:
• Biliary acute pancreatitis (ICD-10 code: K85.1).
• Alcohol induced acute pancreatitis (ICD10 code: K85.2).
• Chronic pancreatitis (ICD10 code: K86.0, K86.1).

120,178 Patients with Non-biliary Non-alcoholic Acute Pancreatitis

93,340 Patients With At Least One Visit

Included for Analysis.

and selected as the matched comparison cohort. Patients in
the two groups were matched for baseline characteristics
including age, gender, race, common comorbidities (diabetes mellitus, obesity, malnutrition, chronic kidney disease,
chronic pulmonary diseases, ischemic heart disease and
heart failure), and visits (inpatient or ambulatory).

2.3
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Follow up and clinical outcomes

The primary outcome of this study was to determine the
incidence of PDAC following APUE in patients aged
40 years or older. We stratified the follow up period to
evaluate the incidence rate at 3 months, and at yearly intervals for one through 5 years following the diagnosis of
acute pancreatitis.
We analyzed both cohorts of PDAC patients (with
and without preceding acute pancreatitis) for other outcomes, specifically the stage of PDAC at diagnosis and
the rate of surgical resection in the first year following
the diagnosis of PDAC. Early-stage PDAC was defined
as diagnosis of PDAC at stage I, stage IIa, or T1–T3 and
N0. Surgical resection was defined as resection procedures performed in the first 12-month period following
the diagnosis of PDAC. Surgical resections were identified by CPT codes for distal subtotal pancreatectomy

(1007918), proximal subtotal pancreatectomy with total
duodenectomy or Whipple-
type procedure (1007923),
pylorus-sparing Whipple-type procedure (1007926),
total pancreatectomy (48155), near-
total pancreatectomy with preservation of duodenum (48146), and total
or subtotal pancreatectomy with autologous islet cell
transplantation (48160). We further identified surgical
procedures through ICD-10-PCS codes, excision of pancreas via open approach (0FBG0ZZ), resection of pancreas via open approach (0FTG0ZZ).
We evaluated serum carbohydrate antigen 19-9 (CA
19-9) and serum carcinoembryonic antigen (CEA) values within a month of acute pancreatitis diagnosis in
patients with and without PDAC. Laboratory codes 9055
(CA 19-9) and 9056 (CEA) were used to identify the results. Abnormal CA 19–9 values were categorized into
two groups, 37 to 100 units/ml and >100 units/ml. Patients
with CEA values >5 ng/ml were identified in each cohort.
We also evaluated the anatomical site of origin of PDAC
where available in both cohorts of patients.

2.4
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Statistical analyses

Mean and standard deviation were calculated for continuous variables, and proportion and percentage were
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calculated for dichotomous and categorical variables.
Fisher's exact tests were used to compare characteristics
(baseline and laboratory). Propensity score matching (1:1)
was performed for baseline characteristics (age at the time
of acute pancreatitis diagnosis, gender, race) and common
morbidities (obesity, diabetes mellitus, chronic kidney disease, chronic pulmonary disease, heart failure, ischemic
heart disease) using a ‘greedy nearest neighbor matching’
approach, and cohorts were considered well matched if
there was a standardized mean difference of less than 0.1
for continuous variables. For clinical outcomes, risk ratio
(RR) with 95% confidence interval (CI) and risk difference
were calculated, and Kaplan-Meir analysis with survival
curve was obtained for primary outcomes.

|

2.5

Survival analysis

A life table was constructed to estimate the incidence
of PDAC in patients with APUE (Tables S1 and S2).
Incidence of PDAC in patients with APUE was calculated
as a new diagnosis of PDAC within 3 months and each
subsequent year for five consecutive years following an
episode of acute pancreatitis. The denominator for this
analysis was the total number of patients with APUE during each specified period. The statistical significance was
set at 2-sided p-value of <0.05. All the statistical analyses
were performed using the TriNetX platform.

|

2.6

Ethical considerations

This study involves human subjects; however, western institutional review board has provided a waiver to TriNetX
as it utilizes aggregate counts and there is no access to protected health information from the participating HCO's.
Thus, written patient consent is not required, nor feasible. Moreover, TriNetX rounds up number of patients to
the nearest 10 for analytic purposes, so that the protected
health information is fortified.20
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R E S U LTS

There were 120,178 patients ≥40 years who were identified and diagnosed with APUE during the study period of
2011–2021. Of these, 93,340 had at least one visit in the
year following acute pancreatitis diagnosis (Figure 1).
The mean age of this cohort was 58.8 (±13.5) years at
the time of diagnosis of acute pancreatitis and 51% were
women. Incidence of PDAC was 1.78% at 3 months, 2.16%
at 1 year, 3.24% at 3 years, and 3.43% at 5 years following
acute pancreatitis (Figure 2A,B).

During the same period, 72,892 adult patients with
PDAC were diagnosed from 48 HCO's. Patients with
chronic pancreatitis and those with biliary, and alcohol-
related pancreatitis were excluded leaving 3902 (5.4%)
patients who were diagnosed with acute pancreatitis in
the year preceding the diagnosis of PDAC. Patients in
the acute pancreatitis cohort were younger (65 years vs.
67 years, p < 0.001), and included more male patients (54%
vs. 52%, p = 0.01) who were more likely to be obese (13.5%
vs. 6.3%, p < 0.001) compared to PDAC patients without
acute pancreatitis. Comorbidities including diabetes mellitus, chronic kidney disease, coronary artery disease,
heart failure and chronic pulmonary diseases were more
common in patients with acute pancreatitis compared to
PDAC patients without acute pancreatitis. Approximately
9% of patients in the acute pancreatitis cohort had pancreatic cysts (excluding pseudocysts) compared to 3% of
PDAC without acute pancreatitis (p < 0.001; Table 1).
Patients with PDAC who had preceding acute pancreatitis underwent surgical resection more often than those
who did not have a preceding diagnosis of acute pancreatitis (10.9% vs. 6.9%, risk ratio, odds ratio 1.58: 95% CI
1.37–1.82). There was a trend toward cancer detection at
an earlier stage in patients with preceding acute pancreatitis compared to other patients with PDAC; however, this
was not statistically significant (p = 0.48; 95% confidence
interval 0.64–2.58) (Table 2). PDAC involved the pancreatic head in majority of patients with APUE (53%) while
body (15%) and tail (7%) were less commonly involved
(Figure 3). About 25% of patients did not have specified
site of PDAC within the pancreas (overlapping areas of
pancreas or unspecified location). Pancreatic head involvement was more common in patients with preceding
acute pancreatitis compared to those without acute pancreatitis (53% vs. 27%, p < 0.001). Elevation of both tumor
markers CA 19–9 (≥37 units/ml, >100 units/ml) and CEA
(>5 ng/ml) was observed more frequently in the acute
pancreatitis cohort compared to those without preceding
acute pancreatitis. CA 19–9 (0.7% vs. 20%) and CEA (0.7%
vs. 7%) were elevated in a much smaller proportion of patients with acute pancreatitis without PDAC compared to
patients with acute pancreatitis and PDAC.
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DISC USSION

Efforts to identify a cost-effective screening strategy to
enable early diagnosis of PDAC can be offset by lack
of clear causal factors or early clinical markers of the
disease for most patients among other barriers. One
of the major initiatives taken to enhance early detection of PDAC was creation of the Chronic Pancreatitis,
Diabetes, and PDAC (CPDPC) Consortium with goals to
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5
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F I G U R E 2 (A) Incidence of pancreatic adenocarcinoma in patients with acute pancreatitis. (B) Probability of developing pancreatic
adenocarcinoma each year after acute pancreatitis.

establish large prospective cohorts of patients for longitudinal follow up.21 Thus far, a diagnosis of new-onset
diabetes within 3 years preceding a diagnosis of PDAC
is one of the best described proximate clinical markers
which may lead to the earlier detection of PDAC; however, the incidence of PDAC in this cohort was still only
1%–2% over a 3-year period, and a previous study has
reported even lower rate (<1%).22,23 Thus, there is a need
to continue pursuit of novel clinical indicators for early
diagnosis of PDAC.
Available data suggest acute pancreatitis is a potential
related factor for PDAC either as a presenting clinical manifestation or an etiological factor for its development.11,15,16
In this large electronic research network study, we observed a significantly increased risk of a PDAC diagnosis
following an episode of APUE. The cumulative incidence

of PDAC ranged from 2.2% by 1 year to 3.4% by 5 years
following a diagnosis of APUE. While our results concur
with previous data of an increased incidence of PDAC in
the first few years following an episode of acute pancreatitis, strikingly, we observed that most of the diagnoses of
PDAC occurred in the first 3 months to 1 year following an
episode of acute pancreatitis.9,19 Patients with PDAC and
APUE were more likely to be younger, obese, and have an
earlier stage-specific PDAC diagnosis (10% vs. 7%), and
more frequently underwent surgical resection (11% vs.
8%) compared to PDAC patients without acute pancreatitis. Overall, these findings are important and novel, and
provide some key insights into the relationship between
acute pancreatitis and PDAC.
While available data suggest an association of acute
pancreatitis and PDAC in a significant minority of

6

|

SINGH et al.

  

TABLE 1

Baseline characteristics of patients with pancreas ductal adenocarcinoma
Mean (±SD)

Number of patients (%)

Demographics

AP

No AP

AP

No AP

p-value

Age (years)

64.9 ± 12.2

66.9 ± 11.9

3902 (100%)

56,870 (100%)

<0.001

Female

—

—

1807 (46.3%)

27,493 (48.3%)

0.01

White race

—

—

2869 (73.5%)

21,388 (72.8%)

0.31

Diagnoses
1009 (25.9%)

8187 (14.4%)

<0.001

Obesity

Diabetes mellitus

528 (13.5%)

3571 (6.3%)

<0.001

Chronic kidney disease

373 (9.6%)

2783 (4.9%)

<0.001

Pancreatic cyst

365 (9.3%)

1911 (3.4%)

<0.001

Ischemic heart disease

621 (15.9%)

4968 (8.7%)

<0.001

Heart failure

252 (6.5%)

2193 (3.9%)

<0.001

30 (0.8%)

182 (0.3%)

<0.001

Tobacco use

Chronic pulmonary disease

123 (3.2%)

784 (1.4%)

<0.001

Pancreatic cyst

365 (9.3%)

1911 (3.4%)

<0.001

Tumor markers
Ca 19-9
37–100 unit/ml

274 (7.0%)

1054 (1.8%)

<0.001

>100 unit/ml

598 (15.3%)

3326 (5.8%)

<0.001

235 (6.0%)

1897 (3.3%)

<0.001

CEA >5 ng/ml
Note: Age, gender and all the listed diagnoses were matched.

Abbreviations: AP, acute pancreatitis; CA 19-9 serum, carbohydrate antigen 19-9; CEA serum, carcinoembryonic antigen; SD, standard deviation.

TABLE 2

Comparing patients with and without preceding pancreas ductal adenocarcinoma

Outcomes
Surgical resection
Early-stage PDAC
Tumor location
Head

a

PDAC with AP

PDAC without AP

Odds ratio (risk difference)

95% CI

p value

10.9% (388)

6.9% (3504)

1.58 (3.8%)

1.37–1.82

<0.001

9.64% (376)

7.23% (4116)

1.3 (2.4%)

0.64–2.58

0.48

53%

27.4%

—

b

—

<0.001

Abbreviations: AP, acute pancreatitis; CI, confidence interval; PDAC, pancreas ductal adenocarcinoma.
a

Stages I and IIa.

b

About 25% patients did not have specified location of cancer.

patients, the question remains whether acute pancreatitis
is an etiologic risk factor for PDAC, or is it an early clinical manifestation of PDAC? Single-center retrospective
studies have reported that the risk of PDAC is highest in
the year following acute pancreatitis followed by a rapid
decrease in incidence over time.12,19 Munigala et al. also
observed that about 90% (69 of 76) of PDAC diagnoses following acute pancreatitis occurred in the first year. These
observations agree with our conclusion that the highest
incidence of PDAC (2.2%) occurs within the first year following a diagnosis of acute pancreatitis. Kirkegard et al.
reported on a Danish registry to evaluate the risk of PDAC
in patients hospitalized with acute pancreatitis, and over
a 10 year follow up period. The risk of PDAC in individuals with acute pancreatitis was observed to be highest

in the first 2 years, however, a significant 2-fold risk increase was sustained for up to 10 years.9 Collectively these
studies indicate the highest risk of PDAC is in the first
1–2 years following acute pancreatitis. This indicated that
in many cases pancreatitis develops as a consequence of
the developing cancer given brief time interval between
the pancreatitis and cancer diagnosis. However, a prior
history of pancreatitis, >2 years has also been reported
more frequently in pancreatic cancer patients compared
with controls.12 Furthermore, individuals with hereditary
pancreatitis have a considerable risk of pancreatic cancer,
indicating in some cases pancreatic cancer may arise due
to underlying pancreatitis.
A retrospective Swedish cohort study followed patients
with acute pancreatitis for up to 10 years and observed an

SINGH et al.

F I G U R E 3 Image depicting location of pancreatic
adenocarcinoma within the pancreas in patients with acute
pancreatitis.

increased incidence of PDAC compared to a non-acute
pancreatitis cohort.10 Although they concluded that the
risk was highest in the first 10 years after acute pancreatitis, approximately 60% of PDAC were diagnosed in
the first year following acute pancreatitis. Similar observations were noted in a prior Swedish study where
the risk of PDAC was highest in the first few years after
acute pancreatitis and declined over the following years.13
Inflammation is an established risk factor for carcinogenesis. Some types of pancreatic cysts are known to be precursors of PDAC and may be missed, or not well characterized
on routine cross-sectional imaging.24,25 Identification of
high-
risk pancreatic cysts (intraductal papillary mucinous neoplasm and mucinous cystic adenomas) during
evaluation of acute pancreatitis may provide an opportunity for heightened surveillance and early diagnosis at
precancerous stage. Pancreatic cysts were detected more
frequently in patients with a preceding diagnosis of acute
pancreatitis (9.3% vs. 3.4%); however, there may be differences in the utilization of pancreatic imaging between the
two groups of patients due to the presence or absence of
acute pancreatitis. We examined the use of endoscopic ultrasound (EUS) for the diagnosis of PDAC and found that
approximately 16% of patients with preceding AP had undergone EUS at the time of PDAC diagnosis compared to
about 12% of patients without preceding AP. Due to lack
of patient-level data we cannot be certain which imaging
modality was utilized for the diagnosis of PDAC at an individual patient level. Furthermore, more frequent use of
EUS in AP cohort may have been related to management
of local complications of AP.
Another important observation from our study was
that head of pancreas cancer occurred approximately
twice as commonly (53% vs. 27%) in patients who had preceding acute pancreatitis compared to those without acute
pancreatitis. These findings are biologically intuitive and
may be explained by the fact that PDAC in the pancreatic
head can cause obstruction of the pancreatic duct leading to pancreatitis, and further supports the argument
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that acute pancreatitis is a clinical manifestation of PDAC
rather than an etiologic entity in many cases.
Retrospective studies have identified that PDAC may
be detected at an earlier stage in patients with a preceding
diagnosis of acute pancreatitis.11,26 A population-based
study comprising Danish and US (Medicare-
eligible)
patients noted a lower frequency of metastatic disease,
higher resection rate, and better survival in patients who
had a diagnosis of acute pancreatitis within 90 days preceding PDAC.16 The findings are limited by the nature of
the administrative database, and all patients with acute
pancreatitis were included irrespective of etiology of acute
pancreatitis.16 Nonetheless, these observations are in-line
with our results and indicate that an earlier diagnosis of
PDAC leads to improved survival.
A key question remains as to whether there is a delay in
the diagnosis of PDAC in patients who present with acute
pancreatitis, and importantly if identification of PDAC is
radiographically challenging in view of acute inflammatory changes, which may take several months to resolve.
It is possible that a neoplastic mass may be mistakenly
missed or occult due to these inflammatory changes, potentially delaying diagnosis.10 Nonetheless, the limited
data available to date including the results herein suggest
the contrary in that the diagnosis of PDAC occurs at an
earlier stage and there is a higher probability of patients
with PDAC and APUE able to undergo surgical resection
compared to PDAC without APUE. We recommend very
close follow up of patients with PDAC and APUE within
the first few years given a 2%–3% risk of being diagnosed
with PDAC in the subsequent 1 to 3 years following acute
pancreatitis. Early use of more sensitive modalities such
as endoscopic ultrasound may be warranted in patients
with acute pancreatitis, especially APUE.
Investigation of isolated, asymptomatic elevation of
CA 19-9 commonly yields benign etiology, including AP,
particularly, acute biliary pancreatitis, chronic pancreatitis and other hepatobiliary diseases.27,28 We observed
that both CA 19-9 and CEA were more commonly elevated in patients with APUE and PDAC compared to
PDAC patients without APUE. An interesting finding
noted in our study is both CA19-9 and CEA were rarely
elevated (<1%) in patients with APUE in the absence of
pancreatic adenocarcinoma. These findings may indicate an opportunity to utilize routine clinical biomarkers such as CA 19-9 and CEA to enrich for possibility
of underlying occult pancreatic adenocarcinoma in
patients with APUE as there appears to be a low likelihood of confounding from acute pancreatitis per se.
Moreover, the common etiology of elevation of CA 19-9
in this setting, including acute biliary pancreatitis, and
chronic pancreatitis, were excluded in both of cohorts.
Retrospective studies have suggested an association

8

|

SINGH et al.

  

between type 2 diabetes mellitus and elevated CEA and
CA 19-9.29,30
Our study has several notable limitations. This study
was designed as a retrospective cohort study and has
an inherent risk of bias, both known and unknown.
Although the database utilizes electronic health records
for research purposes, detailed clinical information of
individual patients is unavailable due to lack of access
to protected health information. As with any other database, conversion of a patient's clinical data into codes
can result in errors. TriNetX performs extensive data
quality assessment to reduce the risk associated with
data collection. Another limitation of using the EHR-
based database is the potential loss of patients if they
transfer their care from one health network to another.
For example, a patient with diagnosis of prior diagnosis of acute pancreatitis receives care for PDAC at a different health network. Furthermore, documentation of
deceased patients may not be uniform, and the cause
of death cannot be determined in individual patients.
Strengths of our study include the recent time frame for
study conduct (2011–2021), the inclusion of considerable number of healthcare organizations from different
regions of the United States and abroad with access to
approximately 70 million patient records, which collectively improves the generalizability of our results.
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CO N C LUSION S

Acute pancreatitis is uncommonly associated with
PDAC and can precede the diagnosis of PDAC in a considerable proportion of patients without another known
etiology of pancreatitis. Patients with a recent episode
of acute pancreatitis are more likely to have PDAC diagnosed at an earlier stage with a higher likelihood of
undergoing surgical resection compared to patients
without acute pancreatitis. CA 19-9 and CEA can act as
potential enrichment biomarkers of underlying PDAC
in patients with APUE and can be utilized in conjunction with imaging modalities, including EUS, for surveillance of these patients given the increased risk of
PDAC over the subsequent 1–3 years. Further prospective studies will inform the relationship between APUE
and PDAC and evaluate whether APUE and PDAC confer a survival advantage relative to patients with PDAC
and without APUE.
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